CD86 and neoplasm: APS reduced tumour volume dose-dependently, with a 50% reduction at 200 mg/kg, increased M1 macrophages (CD86+), and decreased M2 macrophages (CD206+), indicating that APS reshape the tumour immune microenvironment by inhibiting M2 polarisation.